US4781601046
© PR Newswire
13.12.2025
JNJ
LISTED
NYSE
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
News Preview
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa., Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) a...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
JNJ
LISTED
NYSE
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
News Preview
TECVAYLI® and DARZALEX FASPRO® combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-upCombination regimen granted Breakthrough Therapy Designation by U.S. FDAORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
06.12.2025
JNJ
LISTED
NYSE
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
News Preview
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second lineData suggest stronger immune fitness in earlier lines may be associated with longer progression free survivalORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Johnson &am...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
05.12.2025
JNJ
LISTED
NYSE
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
News Preview
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removalPatients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapies for bladder preservationRARITAN, N.J.,...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2025
JNJ
LISTED
NYSE
Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
News Preview
New survey reveals Americans overlook eye health—despite its impact on confidence, independence and early disease detection.JACKSONVILLE, Fla., Dec. 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson, a global leader in eye health, has partnered with Academy Award–nominated actress, producer, and entrepreneur, Naomi...
Themefolio
Profiler
Peergroup
© PR Newswire
17.11.2025
JNJ
LISTED
NYSE
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
News Preview
First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety profile
More than half of TREMFYA®-treated patients across both dose groups achiev...
Themefolio
Profiler
Peergroup
© BusinessWire
17.11.2025
JNJ
LISTED
NYSE
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
News Preview
Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, includ...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
JNJ
LISTED
NYSE
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
News Preview
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring
Landmark approval supports earlier intervention and disease interception of multiple myel...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
JNJ
LISTED
NYSE
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
News Preview
CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2
In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, o...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the Citi’s 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com....
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
News Preview
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm
The Company also announced new data from the pivotal Vibrance-MG study in which pediatric patients receiving treatment with IMAAVY...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
27.10.2025
JNJ
LISTED
NYSE
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
News Preview
Findings highlight opportunity for shared decision-making to improve treatment planning, with more than 90% of patients currently on injectables willing to switch to a new oral therapy with equivalent efficacy and a favorable safety profile
Results show 50.5% of...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
JNJ
LISTED
NYSE
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
News Preview
Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies
TREMFYA® is the only IL-23 inhibitor to demonstrate durable endoscopic and clinical remission with a fully subcutaneous regimen...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
JNJ
LISTED
NYSE
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
News Preview
Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo in the Phase 2b ANTHEM-UC study
Results support Phase 3 c...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2025
JNJ
LISTED
NYSE
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
News Preview
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score
, which is based on 11 key systemic disease domains, at Week 24 versus placebo...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
JNJ
LISTED
NYSE
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
News Preview
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ICONIC-TOTAL study
67% of patients treated with icotrokinra achieved ove...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17th, 2025. Management will participate in a Fireside Chat at 10:40 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
JNJ
LISTED
NYSE
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
News Preview
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients
New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across addi...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
JNJ
LISTED
NYSE
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
News Preview
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company’s common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
News Preview
Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the Company’s intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders.
The intended separation would further strengthen the focus of Johnson & Johnson as an innovation powerhouse, serving area...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
News Preview
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. “Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With a...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company established pursuant to the laws of the Island of Nevis to purchase up to 500,000 shares of Johnson & Johnson common stock at a price of $145.00 per share in cash. Tutanota’s offer price...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
News Preview
17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression
New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 data evaluates the impact on sexual...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the UBS Global Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the UBS Global Healthcare Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archi...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
News Preview
Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study
Clinical and endoscopic outcomes were demonstrated across both biologic-n...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
JNJ
LISTED
NYSE
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
News Preview
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated with the highest dose achieving endoscopic improvement at Week 12 in the Phase 2b ANTHEM-UC study
These data support the promise of a first-in-class targ...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses
News Preview
Studies presented at #Academy25 reveal that ACUVUE OASYS MAX 1-Day for ASTIGMATISM outperformed Dailies Total1® for Astigmatism in patient reported outcomes related to vision and comfort.
Research highlights that the latest ACUVUE cont...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 10:30 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website...
Themefolio
Profiler
Peergroup
© PR Newswire
29.09.2025
JNJ
LISTED
NYSE
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
News Preview
TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six years and older, weighing at least 40 kg
Approval was based...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
News Preview
TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease
TREMFYA® achieved significant rates of clinical remission and endoscopic improvement versus placebo at Week 12 with a subcutaneous induction regimen, consistent with IV induction
Johnson...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
JNJ
LISTED
NYSE
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
News Preview
100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study
TORONTO, Sept. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
JNJ
LISTED
NYSE
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
News Preview
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies
Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study
Robust findings continue...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
JNJ
LISTED
NYSE
Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
News Preview
21 abstracts from across the Company's portfolio highlight clinical and real-world data on major depressive disorder, treatment-resistant depression and schizophrenia
New Phase 3 data demonstrate the safety and efficacy of adjunctive seltorexant compared to quetiapine XR in major depressive disorder with insomnia symptoms
TITUSVILLE, N.J., Sept....
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
JNJ
LISTED
NYSE
U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
News Preview
First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinduction1
Potential practice-changing treatment for certain patients with BCG-unresponsive non-muscle invasive bladder cancer who have limited options bef...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
JNJ
LISTED
NYSE
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
News Preview
Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fireside Chat at 1:10 p.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. A...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
JNJ
LISTED
NYSE
Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
News Preview
Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year
RARITAN, N.J., Sept. 7, 2025 /PR N...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
News Preview
RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment
BARCELONA, Spain, Sept. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT® (amivantama...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
News Preview
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will ho...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
JNJ
LISTED
NYSE
Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress
News Preview
VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE™ Platform in nearly 800 enrolled patientsi
IRVINE, Calif., Sept. 2, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced ac...
Themefolio
Profiler
Peergroup
© PR Newswire
31.08.2025
JNJ
LISTED
NYSE
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
News Preview
MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when compared to standard care, routine use of Impella CP® in patie...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th, 2025. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www....
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
JNJ
LISTED
NYSE
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
News Preview
Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1,2,*,**
WEST CHESTER, Penn., July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System. This AI...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
JNJ
LISTED
NYSE
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
News Preview
Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA®, the only dual-acting IL-23 inhibitor
HORSHAM, Pa., July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the 2025 Wells Fargo Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025. Management will participate in a Fireside Chat at 11:50 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com....
Themefolio
Profiler
Peergroup
© PR Newswire
21.07.2025
JNJ
LISTED
NYSE
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis
News Preview
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor
Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites
Submission und...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
JNJ
LISTED
NYSE
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
News Preview
New Drug Application supported by results from the Phase 2b SunRISe-1 study
RARITAN, N.J., July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine releasing system, for t...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
JNJ
LISTED
NYSE
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company’s common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025.
Abo...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
JNJ
LISTED
NYSE
Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook
News Preview
Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. “Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Our portfolio an...
Themefolio
Profiler
Peergroup
© PR Newswire
08.07.2025
JNJ
LISTED
NYSE
Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo
News Preview
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo
CAPLYTA® is FDA approved to treat schizophrenia and is the first and only approved treatment for bipolar I and II depression as an adjunctive and monotherapy
With the addition of CAPLYTA® to Johnson...
Themefolio
Profiler
Peergroup
© PR Newswire
23.06.2025
JNJ
LISTED
NYSE
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
News Preview
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG
IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living...
Themefolio
Profiler
Peergroup
© PR Newswire
15.06.2025
JNJ
LISTED
NYSE
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
News Preview
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA
Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs
MILAN, June 15, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: J...
Themefolio
Profiler
Peergroup
© PR Newswire
13.06.2025
JNJ
LISTED
NYSE
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
News Preview
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease
75-80% complete response rate among evaluable patients at the recommended Phase 2 dose
MILAN, June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today th...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
JNJ
LISTED
NYSE
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
News Preview
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML
Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation
MILAN, June 12, 2025 /PRNewswire/ -- Johnson...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
JNJ
LISTED
NYSE
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
News Preview
TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study
More than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24
Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety p...
Themefolio
Profiler
Peergroup
© BusinessWire
10.06.2025
JNJ
LISTED
NYSE
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
News Preview
Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/
“We are thrilled to have Daniel join Johnson & Johnson’s Board of Directors,” s...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
JNJ
LISTED
NYSE
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
News Preview
More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS study
Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO® in transplant-ineligible newly diagnosed patients
CHICAGO, June 3, 20...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
JNJ
LISTED
NYSE
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
News Preview
New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI® remain progression-free
CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today ne...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
